203 related articles for article (PubMed ID: 15962637)
21. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain.
Arribas-Mir L; Rueda-Lozano D; Agrela-Cardona M; Cedeño-Benavides T; Olvera-Porcel C; Bueno-Cavanillas A
Contraception; 2009 Nov; 80(5):457-62. PubMed ID: 19835720
[TBL] [Abstract][Full Text] [Related]
22. Implanon use in Thai women above the age of 35 years.
Booranabunyat S; Taneepanichskul S
Contraception; 2004 Jun; 69(6):489-91. PubMed ID: 15157794
[TBL] [Abstract][Full Text] [Related]
23. [Acceptability of the etonogestrel-containing contraceptive implant (Implanon)].
Sergent F; Clamageran C; Bastard AM; Verspyck E; Marpeau L
J Gynecol Obstet Biol Reprod (Paris); 2004 Sep; 33(5):407-15. PubMed ID: 15480280
[TBL] [Abstract][Full Text] [Related]
24. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study.
Walch K; Unfried G; Huber J; Kurz C; van Trotsenburg M; Pernicka E; Wenzl R
Contraception; 2009 Jan; 79(1):29-34. PubMed ID: 19041438
[TBL] [Abstract][Full Text] [Related]
25. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives.
Sabatini R; Cagiano R
Contraception; 2006 Sep; 74(3):220-3. PubMed ID: 16904415
[TBL] [Abstract][Full Text] [Related]
26. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database.
Murphy PA; Brixner D
Contraception; 2008 Apr; 77(4):257-63. PubMed ID: 18342648
[TBL] [Abstract][Full Text] [Related]
27. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand.
Kiriwat O; Patanayindee A; Koetsawang S; Korver T; Bennink HJ
Eur J Contracept Reprod Health Care; 1998 Jun; 3(2):85-91. PubMed ID: 9710712
[TBL] [Abstract][Full Text] [Related]
28. Australian women's experience with Implanon.
Weisberg E; Fraser I
Aust Fam Physician; 2005 Aug; 34(8):694-6. PubMed ID: 16113711
[TBL] [Abstract][Full Text] [Related]
29. Etonogestrel implant as a contraceptive choice; patient acceptability and adverse effect profile in a general practice setting.
Riney S; O'Shea B; Forde A
Ir Med J; 2009 Jan; 102(1):24-5. PubMed ID: 19284015
[TBL] [Abstract][Full Text] [Related]
30. Early implanon discontinuation and associated factors among women ever used implanon in Mettu district, Oromia regional state, southwest Ethiopia, 2021.
Tesfaye H; Negara E; Bayisa K
Reprod Health; 2021 Aug; 18(1):176. PubMed ID: 34454512
[TBL] [Abstract][Full Text] [Related]
31. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience.
Graesslin O; Korver T
Eur J Contracept Reprod Health Care; 2008 Jun; 13 Suppl 1():4-12. PubMed ID: 18330813
[TBL] [Abstract][Full Text] [Related]
32. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
33. [Insertion problems, removal problems, and contraception failures with Implanon].
Bensouda-Grimaldi L; Jonville-Béra AP; Beau-Salinas F; Llabres S; Autret-Leca E;
Gynecol Obstet Fertil; 2005 Dec; 33(12):986-90. PubMed ID: 16321557
[TBL] [Abstract][Full Text] [Related]
34. Implanon. The new alternative.
Cherry S
Aust Fam Physician; 2002 Oct; 31(10):897-900. PubMed ID: 12404826
[TBL] [Abstract][Full Text] [Related]
35. Implant contraception in Singaporean women: one decade of experience in KK Women's and Children's Hospital.
Kang W; Tan KH
Singapore Med J; 2004 Oct; 45(10):482-6. PubMed ID: 15455169
[TBL] [Abstract][Full Text] [Related]
36. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting.
Lakha F; Glasier AF
Contraception; 2006 Oct; 74(4):287-9. PubMed ID: 16982226
[TBL] [Abstract][Full Text] [Related]
37. Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years.
Pongsatha S; Ekmahachai M; Suntornlimsiri N; Morakote N; Chaovisitsaree S
Int J Gynaecol Obstet; 2010 Jun; 109(3):223-5. PubMed ID: 20206353
[TBL] [Abstract][Full Text] [Related]
38. Reasons for Discontinuation of Implanon among Users in Buffalo City Metropolitan Municipality, South Africa: A Cross-Sectional Study.
Mrwebi KP; Goon DT; Owolabi EO; Adeniyi OV; Seekoe E; Ajayi AI
Afr J Reprod Health; 2018 Mar; 22(1):113-119. PubMed ID: 29777648
[TBL] [Abstract][Full Text] [Related]
39. Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors.
Merki-Feld GS; Imthurn B; Seifert B
Clin Endocrinol (Oxf); 2008 Mar; 68(3):355-60. PubMed ID: 17854390
[TBL] [Abstract][Full Text] [Related]
40. Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group.
Bitzer J; Tschudin S; Alder J;
Eur J Contracept Reprod Health Care; 2004 Dec; 9(4):278-84. PubMed ID: 15799185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
